RecruitingPhase 2NCT05489211

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours

Sponsor

AstraZeneca

Enrollment

454 participants

Start Date

Sep 6, 2022

Study Type

INTERVENTIONAL

Conditions

Gastric Cancer Ovarian Cancer Endometrial Cancer Metastatic Castration-resistant Prostate Cancer

Summary

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

Eligibility

Min Age: 18 YearsMax Age: 130 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new antibody-drug combination called Dato-DXd — either alone or with other cancer treatments — in patients with advanced or spread cancers including lung, breast, bladder, and prostate cancers. The drug is designed to find cancer cells and deliver chemotherapy directly to them. **You may be eligible if...** - You are 18 or older with advanced or metastatic cancer - You are in reasonably good physical health (able to carry out daily activities) - Your cancer is measurable on scans - Your bone marrow and organ function meet certain blood test thresholds - You have a life expectancy of at least 12 weeks - You are willing to provide a tumor tissue sample - Women of childbearing potential must use effective contraception **You may NOT be eligible if...** - You have certain serious lung conditions or active lung inflammation - You have uncontrolled eye conditions (corneal disease) - You have uncontrolled infections or other serious medical issues - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDatopotamab deruxtecan (Dato-DXd)

Intravenous (IV) Antibody drug conjugate

DRUGCapecitabine

Administered orally

DRUG5-Fluorouracil

Administered as an IV

DRUGVolrustomig

Administered as an IV

DRUGCarboplatin

Administered as an IV

DRUGBevacizumab

Administered as an IV

DRUGRilvegostomig

Administered as an IV

DRUGPrednisone/ prednisolone

Administered orally

DRUGCisplatin

Administered as an IV

Locations(95)

Research Site

Los Angeles, California, United States

Research Site

San Diego, California, United States

Research Site

Santa Rosa, California, United States

Research Site

Muncie, Indiana, United States

Research Site

Kansas City, Kansas, United States

Research Site

Boston, Massachusetts, United States

Research Site

Boston, Massachusetts, United States

Research Site

Grand Rapids, Michigan, United States

Research Site

East Brunswick, New Jersey, United States

Research Site

Albuquerque, New Mexico, United States

Research Site

Commack, New York, United States

Research Site

Cincinnati, Ohio, United States

Research Site

Columbus, Ohio, United States

Research Site

Portland, Oregon, United States

Research Site

Nashville, Tennessee, United States

Research Site

Nashville, Tennessee, United States

Research Site

Houston, Texas, United States

Research Site

Madison, Wisconsin, United States

Research Site

Toronto, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Montreal, Quebec, Canada

Research Site

Montreal, Quebec, Canada

Research Site

Québec, Quebec, Canada

Research Site

Changsha, China

Research Site

Chongqing, China

Research Site

Guangzhou, China

Research Site

Guangzhou, China

Research Site

Hangzhou, China

Research Site

Hefei, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shenyang, China

Research Site

Wuhan, China

Research Site

Wuhan, China

Research Site

Xi'an, China

Research Site

Zhengzhou, China

Research Site

Bordeaux, France

Research Site

Lyon, France

Research Site

Marseille, France

Research Site

Suresnes, France

Research Site

Berlin, Germany

Research Site

Essen, Germany

Research Site

Hanover, Germany

Research Site

München, Germany

Research Site

Regensburg, Germany

Research Site

Florence, Italy

Research Site

Genova, Italy

Research Site

Milan, Italy

Research Site

Milan, Italy

Research Site

Milan, Italy

Research Site

Naples, Italy

Research Site

Rome, Italy

Research Site

Chūōku, Japan

Research Site

Kashiwa, Japan

Research Site

Kōtoku, Japan

Research Site

Nagoya, Japan

Research Site

Shinagawa-ku, Japan

Research Site

Suita-shi, Japan

Research Site

Gliwice, Poland

Research Site

Krakow, Poland

Research Site

Lodz, Poland

Research Site

Poznan, Poland

Research Site

Warsaw, Poland

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Seoul, South Korea

Research Site

Barcelona, Spain

Research Site

Córdoba, Spain

Research Site

Madrid, Spain

Research Site

Málaga, Spain

Research Site

Pamplona, Spain

Research Site

Seville, Spain

Research Site

Basel, Switzerland

Research Site

Bellinzona, Switzerland

Research Site

Sankt Gallen, Switzerland

Research Site

Liou Ying Township, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taipei, Taiwan

Research Site

Taoyuan, Taiwan

Research Site

Ankara, Turkey (Türkiye)

Research Site

Ankara, Turkey (Türkiye)

Research Site

Cordaleo, Turkey (Türkiye)

Research Site

Edirne, Turkey (Türkiye)

Research Site

Kadıkoy/Istanbul, Turkey (Türkiye)

Research Site

Konya, Turkey (Türkiye)

Research Site

Pamukkale, Turkey (Türkiye)

Research Site

Samsun, Turkey (Türkiye)

Research Site

Cambridge, United Kingdom

Research Site

Dundee, United Kingdom

Research Site

London, United Kingdom

Research Site

London, United Kingdom

Research Site

London, United Kingdom

Research Site

Manchester, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05489211

Related Trials

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

NCT045579691 location

DESTINY-PANTUMOUR04

NCT0712400017 locations

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT0621891418 locations

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT0731855828 locations

Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics

NCT067605071 location